ARTICLE | Company News
AVI BioPharma, Eleos deal
January 15, 2007 8:00 AM UTC
The companies signed a cross-license agreement to develop antisense compounds targeting p53. Eleos gets an exclusive license to AVII's Neugene antisense chemistry to develop compounds targeting p53 to...